NATA CME Webinar – Haemostatic monitoring and clinical decision making in patients with COVID–19-induced coagulopathy

The objective of this webinar is to provide participants with an update on the assessment and the management of coagulopathy associated with COVID–19.

Monday, March 29, 2021, 17:45–19:00 CEST (UTC +2)

Register for the webinar
(free registration)

Welcome and introduction
Jens Meier, Linz, Austria

Pathophysiology of COVID–19-induced coagulopathy
Jecko Thachil, Manchester, UK

Haemostatic monitoring in COVID–19 patients: laboratory tests and viscoelastic assays
Mauro Panigada, Milan, Italy

Management of coagulopathy in COVID–19 patients: what is current guidance?
Saskia Middeldorp, Nijmegen, The Netherlands

Interactive panel discussion
All faculty

Concluding comments
Marco Ranucci, Milan, Italy

Educational objectives

After completing this educational activity, learners should be able to:

• Describe the mechanisms of coagulopathy associated with coronavirus disease 2019 (COVID–19)
• Explain the similarities and differences between COVID–19-induced coagulopathy and disseminated intravascular coagulation (DIC)
• Evaluate the role of haemostatic monitoring (laboratory tests and viscoelastic assays) in the management of patients with COVID–19-associated coagulopathy
• Discuss currently available evidence and knowledge gaps on the management of COVID–19-induced coagulopathy

This webinar is organised by NATA and supported by an unrestricted educational grant from Haemonetics.